M

Mass General Brigham

Early-stage life science venture investor

Imaging Tech

Full-TimeUpdated on 10/23/2026
$36.52 - $69.31/hr+ Differentials + Premiums + Bonuses
Mid
Bachelor's
Nantucket, MA, USA
In PersonOnsite at 57 Prospect Street; frequent on-call work and rotating shifts.
Medical, Clinical & VeterinaryDiagnostics & Laboratory Professionals

About the job

Requirements
  • Graduate of a program accredited by the Joint Review Committee on Education in Radiologic Technology.
  • ARRT (R) and ARRT (CT), ARRT (M), or ARRT (MR) registration is required.
  • Must be registered, proficient, and able to work unsupervised in two modalities.
  • Current applicable state licenses are required.
  • Basic Life Support/CPR certification is required within one week of hire; American Heart Association and American Red Cross certifications are accepted.
  • Must demonstrate adequate technical skills and judgment to function unsupervised during on-call, second-shift, and weekend hours.
  • Must possess interpersonal skills to interact effectively with patients experiencing physical or emotional stress.
  • Must possess analytical abilities to acquire and effectively use knowledge of imaging processes, techniques, and procedures.
  • Must be able to adapt to changing department pace and frequent interruptions.
  • Must have a comprehensive understanding of computer operations relating to patient information and management, including CPSI and PACS.
  • Must be aware of departmental hazards, including ionizing radiation and universal precautions, and adhere to hospital and regulatory safety standards.
  • Must be able to relay information concisely to the department director, radiologist, staff, patients, and other hospital personnel.
  • Must be able to perform essential job duties.
  • Must be flexible with work schedule, including hours and days, and available for frequent on-call work and in the case of a hospital-declared emergency.
  • Must meet applicable licensure and continuing education requirements under governing regulations and department policy.
Responsibilities
  • Position patients and set technical factors for diagnostic procedures; maintain high standards for film and image quality.
  • Follow department exam protocols and complete ordered exams according to protocol, documenting why an exam is not completed as prescribed.
  • Independently identify and perform needed duties, establish priorities, organize work and time, use time effectively, and avoid misuse of supplies, equipment, and services.
  • Modify patient protocols to accommodate physical and cognitive abilities, discuss issues with the radiologist, and document patient information appropriately.
  • Greet patients by confirming identification, reviewing imaging requests and special instructions, and confirming the anticipated service.
  • Ensure exams are accurately labeled with patient identification, date, technologist identification, and exam time.
  • Follow hospital policies to reduce wrong-site, wrong-patient, and wrong-procedure risks.
  • Comply with HFAP, TJC, local regulatory, CMS, state, and federal requirements.
  • Maintain medical and surgical aseptic procedures and follow infection-control guidelines, including standard and transmission-based precautions.
  • Assess pain that interferes with imaging and contact a physician for intervention as appropriate.
  • Understand and participate in new and ongoing process-improvement activities; assist with the performance-improvement program, organize its documents, and produce them on demand.
  • Maintain a neat and clean workplace in accordance with hospital standards.
  • Work at a pace consistent with departmental standards and assist radiologists with therapeutic procedures by preparing supplies and techniques.
  • Inform and educate patients and families about procedures.
  • Reduce healthcare-acquired infection risks through proper handwashing and equipment disinfection.
  • Document medication reactions and infiltrations on the appropriate form.
  • Work to improve communication among caregivers.
  • Plan and assign work efficiently according to department guidelines.
  • Conduct job-specific orientation and on-the-job training for department employees.
  • Handle complaints professionally and efficiently and report them to the department director promptly.
  • Verify studies for accuracy and quality in PACS before radiologist interpretation.
  • Use equipment safely and carefully, and report malfunctions and request service according to department protocol.
  • Attend scheduled and mandatory in-service sessions and communicate ideas to supervisors for safer equipment, tool, and process layouts.
  • Demonstrate courteous and appropriate telephone skills.
  • Meet attendance and punctuality requirements, provide proper notice of absences or tardiness, and take corrective action to prevent recurrence.
  • Perform other assigned or required duties.
  • Set radiographic technical factors to minimize patient dose, use radiation-safety techniques, shield patients when appropriate, follow safety standards for patients, employees, and family members, and determine pregnancy status before imaging women of childbearing age.
  • Wear a radiation dosimetry badge according to protocol and use personal protective equipment appropriately.
  • Perform bedside and operating-room radiographic exams for patients unable to be imaged in the Radiology Service, provide diagnostic X-rays to surgeons and professional staff, and operate the operating-room fluoroscopy unit.
  • Oversee mammography regulatory compliance as defined by the FDA and ACR.
  • Apply established protocols and equipment-operation knowledge when performing mammography quality-control testing.
  • Coordinate activities and tasks to maintain mammography quality compliance and accreditation.
  • Organize and facilitate annual inspections and documentation required by the Mammography Quality Standards Act or ACR.
  • Work with mammography technologists, physicians, registered nurses, physicists, and field service engineers to ensure compliance with Mammography Quality Standards Act regulations.
  • Provide instruction and feedback to technologists.
  • Operate CT equipment according to departmental protocols to obtain diagnostic images and information; prepare, position, and immobilize patients; select imaging factors; and image designated body parts.
  • Check calibration and verify proper operation of equipment before use, and notify appropriate personnel of malfunctions and needed repairs.
  • Perform intravenous insertion for contrast injection.
  • Operate MRI equipment according to departmental protocols to obtain diagnostic images and information; screen, prepare, position, and immobilize patients; select imaging factors; and image designated body parts.
  • Screen MRI patients for contraindications such as cardiac pacemakers, aneurysm clips, stapedectomy, and eye surgery, and check laboratory results for contraindications to gadolinium contrast agents when appropriate.
  • Identify potential hazards within the MRI unit, including metal objects and unscreened personnel or patients, and adhere to hospital and regulatory safety standards.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.

Associated Press
May 13th, 2026
Violet Therapeutics raises $4.75M to advance synaptic preservation therapy for neurodegenerative diseases

Violet Therapeutics, a biotechnology company developing therapies for neurodegenerative diseases, has raised $4.75 million in a seed extension round led by Lifespan Vision Ventures. Dementia Discovery Fund, UTEC, Ono Venture Investment and Mass General Brigham Ventures also participated. The Cambridge-based company will use the funding to advance its lead small molecule programme targeting EphB3 through IND-enabling activities. The therapy aims to halt and potentially reverse cognitive decline through glial-mediated synaptic preservation, addressing synaptic loss, the strongest predictor of cognitive decline in Alzheimer's and other neurodegenerative diseases. Violet's proprietary CONNECT platform maps cell-cell interaction networks to identify novel therapeutic targets. Founded by Mass General Brigham Ventures with researchers from Brigham and Women's Hospital, the company is developing first-in-class CNS therapies.